Online alışverişlerinizde %10 iskonto uygulanır
English Ι Türkçe
botiss dental » L-PRF™

L-PRF™

Leukocyte-Platelet Rich Fibrin


L-PRF™ is a 3-D autogenous combination of Platelet Rich Fibrin derived from the patient’s blood1. A simplified chairside procedure results in the production of a thin, compressed layer of platelet rich fibrin that is strong, pliable and suitable for suturing. This natural fibrin network is rich in platelets, growth factors and cytokines that are derived from the blood platelets and leukocytes1.


The presence of these proteins have been reported to produce rapid healing, especially during the critical first seven days after placement2. This network promotes more efficient cell migration and proliferation without chemical or bovine thrombin additives3.


Properties

  • Simple and economic4
  • Natural - 100% autologous4
  • Thin Fibrin Matrix & Plugs4
  • Leukocytes, Platelets and Fibrin1
  • Slow Release at ≤ 7 days1
  • Matrix for Bone Graft Material5

  • No Anticoagulant
  • No Bovine Thrombin
  • No Heating
  • No Pipetting
  • No Second Spin
  • No Chemical Additives
  • No Expensive Consumables

Clinically, Leukocyte-Platelet Rich Fibrin displays excellent working properties. This biomaterial is resilient, strong and pliable, making it easy to manipulate. It can be cut to size, and is supple enough to adapt to many anatomical areas. It is adhesive in nature and very receptive to suturing. In addition, there is ample working time since L-PRF™ is stable at room temperature for several hours4.


Indications (Dental/Oral and Maxillofacial Surgical Sitesen)

L-PRF™ improves wound healing after dental and maxillofacial surgeries7. The application of L-PRF™ is recommended in combination with all botiss soft and hard tissue regeneration materials, e.g. in:

  • Sinus floor elevation4
  • Extraction sockets1,4,5,6
  • Augmentation procedures5

1Dohan Ehrenfest DM, Del Corso M, Diss A, et al. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. J Periodontol. 2010 Apr;81(4):546-55.
2Dohan Ehrenfest, David M.; de Peppo, Giuseppe; Doglioli Pierre; Sammartino Gilberto. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. Volume 27, Number 1, February 2009, pp. 63-69(7)
3Dohan DM,, Diss A, Dohan SL, Dohan AJ, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endo. 2006 Mar; 101(3):e51-5.
4Michael Toffler, Nicholas Toscano, Dan Holtzclaw, DDS, et al.Introducing Choukroun's Platelet Rich Fibrin (PRF) to the Reconstructive Surgery Milieu. J Implant & Adv Clin Dent. 2009 Sept; 1(6): 21-32.
5Simonpieri A, Del Corso M, Vervelle A, Jimbo R, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. Curr Pharm Biotechnol 2012 Jun;13(7):1231-56.
6Del Corso M, Mazor Z, Rutkowski JL, et al. The use of leukocyte- and platelet-rich fibrin during immediate postextractive implantation and loading for the esthetic replacement of a fractured maxillary central incisor. J Oral Impl 2012 Apr;38(2):181-7.
7Jain V, Triveni MG, Kumar AB, Mehta DS. Role of platelet-rich-fibrin in enhancing palatal wound healing after free graft. Contemp Clin Dent. 2012 Sep;3(Suppl 2):S240-3.
8Soadoun AP, Touati B. Soft tissue recession around implants: Is it still unavoidable? --Part II. Pract Proced Aesthet Dent. 2007 Mar;19(2):81-7.


Downloads:

L-PRF Clinical Cases Clinical Cases


ALL Centrifuge 001


004


005

006

007


008


009


010


011

012


© 2013 - 2017 botiss.com.tr